Lead Product(s) : Vixotrigine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Details : Phase 2 CONVEY study of vixotrigine (BIIB074), a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN).
Brand Name : BIIB074
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : Vixotrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?